Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy

Fig. 5

A schematic diagram of the proposed mode of action of a TEDbody in cancer immunotherapy. A TEDbody delivers a fused MHC-I-restricted viral CTL epitope peptide into the cytosol of integrin αvβ5-expressing cancer cells to be processed for surface presentation by cognate MHC-I, thereby rendering the marked cancer cells recognizable and killable by pre-existing antiviral CTLs arising from common human viral infections in cancer patients as follows: 1) binding to the tumor-associated receptor, integrin αvβ5, for cellular internalization; 2) cytosolic localization through endosomal escape; 3) proteasomal cleavage and degradation generating CTL epitope precursor peptides; 4) ER uptake by TAP and N-terminal trimming of the precursor peptides to generate the mature CTL epitope, followed by its binding to cognate MHC-I; 5) cell surface presentation of the pMHCI through the ER-to-Golgi pathway; 6) recognition and lysis of pMHCI-presenting cells by pre-existing pMHCI-specific antiviral CTLs

Back to article page

Molecular Cancer

ISSN: 1476-4598